Cure Genetics to Develop AAV Vectors for Neuro Startup in $60 Million Deal
publication date: Sep 15, 2023
Suzhou Cure Genetics, a cell and gene therapy company, announced a $60 million deal to create AAV vectors for Hong Kong’s Frametact, a neurodegenerative disease startup. Frametact was founded by a molecular neuroscience research team at The Hong Kong University of Science and Technology and Hong Kong Center For Neurodegenerative Diseases. It targets familial diseases that include Alzheimer's, Parkinson's and Huntington's disease. Cure, which will apply its VELP™ platform to develop novel Adeno-Associated Virus (AAV) vectors, will receive $60 million in upfront and milestone payments, plus royalties on revenues. More details...
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.